Belite Bio (BLTE) Intangibles (2024 - 2025)
Belite Bio's quarterly Intangibles came in at $19000.0 in Q4 2025, down 38.71% year-on-year from $31000.0 in Q4 2024, and down 38.71% quarter-over-quarter from $31000.0 in Q4 2024.
Belite Bio has reported Intangibles for 2 years, with the latest figure at $19000.0 in Q4 2025.
- For the quarter ending Q4 2025, Intangibles fell 38.71% year-over-year to $19000.0; the trailing twelve-month figure through Dec 2025 stood at $19000.0 (down 38.71% YoY), and the FY2025 full-year result was $19000.0, down 38.71% from the prior year.
- Intangibles for Q4 2025 stood at $19000.0, down from $31000.0 in the prior quarter.
- The five-year high for Intangibles was $31000.0 in Q4 2024, with the low at $19000.0 in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.41 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 11,640.44 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 418.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.29 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Belite Bio | 4.92 Bn | 4.45 Bn | - | 19,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 19,000.00 |
| Sep 30, 2025 | 24,000.00 |
| Dec 31, 2024 | 31,000.00 |